One-line thesis. HCA is the largest for-profit hospital operator in the US — a genuinely cheap (13.6× FY26E), high-return (~19% ROIC), prodigious cash generator that shrinks its share count aggressively — but it carries heavy leverage (3.1× net-debt/EBITDA, negative book equity) and sits directly in the path of two US policy changes (ACA subsidy expiry, Medicaid payment reform), which is why the stock is down 25% from its high and why this is a tactical value buy, not a core holding.
◆ Synthos call — HoldHCA is a solid business largely reflected at ~$500 — fine to keep, no reason to chase; it gets interesting again below ~$425.
Downside Risk (lower = safer)
6/10 · High
Cheap at 13.6× FY26E, but 3.1× net-debt/EBITDA, negative book equity & ACA/Medicaid policy overhang.
Mature acute-care operator; growth is steady-to-decelerating, not accelerating — this is a compounder, not an exponential.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 13%/yrTo justify today’s $410, earnings would have to compound roughly 13% a year for 10 years (9% discount rate). Analysts forecast ~12%/yr, so the market is pricing in about what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
HCA runs 189 hospitals and about 2,600 clinics, surgery centers and ERs across 19 US states and the UK. When you're admitted to a hospital, someone pays the bill — a private insurer, Medicare (for seniors), or Medicaid (for lower-income patients). HCA's profit depends heavily on which of those is paying, because private insurers pay the most.
Is the stock cheap or expensive? Cheap. You're paying about $14 for every $1 the company earns per year — roughly half what the average big company costs. The market marked it down because of worries in Washington, not because the business is broken. Our verdict is Buy — Tactical: a good value if you can stomach some political headline risk, but not a "buy and forget for a decade" stock.
Here's what our three scores mean in everyday terms:
Downside Risk 6/10 (a bit above average). The price is low, which protects you — but the company owes a lot of money and its profits swing with government healthcare rules.
Growth Quality 6/10 (solid, not spectacular). It grows steadily and earns strong returns, and it boosts per-share earnings by buying back its own stock — but the underlying business grows slowly, at roughly the pace of the healthcare system.
Exponential Potential 3/10 (low). This is a big, mature company. Don't expect it to double overnight; expect steady grinding.
The one big worry: US healthcare politics. If enhanced insurance subsidies expire and more patients become uninsured, or if Medicaid changes how it pays hospitals, HCA's profits take a hit. That is the whole reason the stock is on sale.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago
Solid = HCA · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$410.50
Market cap$91B
P/E trailing18×
P/E FY26E / FY27E14× / 12×
EV / Sales1.8×
EV / EBITDA8.9×
Gross margin34.9%
Net margin8.9%
Dividend yield0.73%
Beta1.134
52-wk range$334 – $545
RSI(14)69
50 / 200-DMA$404 / $460
12-mo return+5% (SPY +21%)
Street target$505 ($413–$635)
Analyst grades30 Buy · 14 Hold · 2 Sell
FMP ratingB-
Next earnings2026-08-05
What the experts actually said 0 traceable claims on HCA · showing the highest-conviction voices
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
HCA Healthcare (NYSE: HCA) is the largest publicly traded operator of acute-care hospitals in the United States, founded in 1968 and headquartered in Nashville. As of Q1'26 it ran 189 hospitals and ~2,600 ambulatory sites (surgery centers, freestanding ERs, urgent-care and physician clinics) across 19 states plus the United Kingdom, with ~320,000 employees. CEO: Sam Hazen. Fiscal year ends December 31. It is controlled-adjacent — the Frist family (founders) remain 10%+ owners and hold board seats.
Revenue mix (FY2025, from filings — this is a payer-mix business, so the segmentation is by who pays):
By payer: Managed Care & other insurers $36.97B (49%) · Managed Medicare $13.44B · Medicare $11.27B · Medicaid $5.91B · Managed Medicaid $3.69B · International $1.86B. The ~49% commercial/managed-care slice is where the margin is — a shift of patients from commercial to Medicaid/uninsured is the core earnings risk (§11).
By geography (operating groups): American Group $26.45B · Atlantic Group $24.71B · National Group $21.28B — a diversified, multi-state US footprint (Texas and Florida are the largest states).
The business model: own dense hospital networks in high-growth Sun Belt markets, run them at scale, generate large cash flow, and return it almost entirely to shareholders via buybacks and a modest dividend. This is a capital-return compounder, not a growth story.
2. The expert thesis
There is no expert coverage of HCA in the Synthos knowledge base.total_claims = 0, zero net-bullish voices, zero cautionary voices. None of the tracked expert panel (the podcast/analyst voices Synthos distills) has an on-record, traceable view on HCA that cleared our ingestion bar.
What that means for this note: the verdict is entirely fundamentals- and quant-driven. We are not borrowing anyone's conviction, and — per the Synthos house standard — we cite no claim_ids because none exist. Where a normal Synthos deep dive would triangulate expert theses against the numbers, here you get only the numbers and our own scenario model. Weight this accordingly: it is an honest quantitative read, not a high-conviction, breadth-backed call. That is also why conviction is logged Low and the position sizing is tactical (§12).
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
6 · Moderate-High
Valuation is a cushion (13.6× FY26E, well below market), but 3.1× net-debt/EBITDA, negative book equity (−$6.0B, a buyback artifact), beta 1.13, a −25% drawdown already underway, and direct exposure to ACA-subsidy/Medicaid policy shocks push risk above average.
Growth Quality
6 · Solid
~5% forward revenue CAGR and a 20% EBITDA margin with ~19% ROIC and ~9% FCF yield are genuinely high-quality; but reported EPS growth (~11% CAGR) is substantially buyback-manufactured, and the moat is regional density, not a franchise.
Exponential Potential
3 · Low
A mature, ~$76B-revenue acute-care operator growing mid-single-digits. Growth is steady-to-decelerating, not accelerating; there is no obvious second derivative. Own it for cash return and value re-rating, not for a multibagger.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
Policy overhang clears (subsidies extended or impact modest); volumes stay firm; buyback continues shrinking the count. FY27E EPS beats to ~$35 (vs $33.18 cons); multiple re-rates to ~16.5×.
~$578 (+41%)
Base(our anchor)
Estimates roughly hit — FY27E EPS $33.18; a steady cash-compounder with policy noise earns a ~15× multiple (still below market).
Synthos fair value = the base case, ~$500 (+22%), with the full $360–$578 span as the honest range. Our base sits essentially on top of the Street's $504.73 consensus — this is one of the rare cases where our independent model and the sell-side land in the same place, which raises our confidence in the number even as the conviction stays Low for lack of expert breadth. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). HCA is squarely a compounder, and a mature one:
Forward growth: revenue CAGR FY25→FY30E ~5.3% ($75.6B → $97.96B est); EPS CAGR ~11.2% ($28.62 → $48.73 est) — the gap between the two is the buyback doing the work.
Acceleration (the 2nd derivative) is flat-to-negative: revenue grew +7.1% (FY25) and the estimate stream implies ~+3.9% (FY26E) → +4.8% (FY27E) → ~+5.5% (FY28E) — mid-single-digit, no inflection. Q1'26 revenue was up just 4.3% YoY, partly on a weak respiratory season. There is no acceleration story here. Per our flagship philosophy we hunt forward next-exponentials; HCA is the opposite archetype — a trailing/steady compounder.
Room to run: the US hospital market is enormous but HCA is already the largest for-profit operator; share gains are incremental (M&A, new facilities in Sun Belt markets), not exponential. TAM is not the binding constraint — the growth rate is.
Reinvestment runway: ~$4.9B/yr capex into facilities is productive (fuels the ~19% ROIC), but it funds mid-single-digit organic growth, not a step-change.
Exponential Potential: Low (3/10). This is not a criticism of the business — it is an honest label. Own HCA for its cheap valuation, ~9% FCF yield and relentless buyback, not for exponential upside. A small, accelerating name would score 8–9 here; HCA earns a 3.
Revenue: FY25 $75.6B, +7.1% (FY24 $70.6B, +8.7% on FY23 $65.0B). Steady mid-to-high-single-digit growth at scale.
Quarterly trajectory: Q1'25 $18.32B → Q2 $18.61B → Q3 $19.16B → Q4 $19.51B → Q1'26 $19.11B (+4.3% YoY). Q1'26 softened on a weak respiratory season and a January winter storm (per the earnings release), partly offset by Medicaid supplemental recognition.
Margins: gross ~34.9% TTM, EBITDA margin ~20.5% TTM ($15.6B FY25 EBITDA), operating ~15.8%, net ~8.9% TTM. Stable, characteristic of a hospital operator (thin net margin, high asset turnover).
Earnings: net income $6.78B FY25 (EPS $28.62, diluted $28.38), up from $5.76B FY24. TTM diluted EPS ~$29.25. Q1'26 net income $1.62B, EPS $7.15 (+10.9% YoY on a smaller share count).
Cash flow: operating CF $12.64B FY25, capex −$4.94B, FCF $7.69B (FCF yield ~8.7%) — the defining strength. FCF funded $10.07B of buybacks in FY25 (plus $0.68B dividends), which is why the share count fell.
Balance sheet (the caution flag): total debt $50.2B, net debt $49.2B, net-debt/EBITDA ~3.1×. Total stockholders' equity is negative (−$6.0B) — this is not distress; it is the mechanical result of buying back more stock (at market prices) than cumulative retained earnings, common among aggressive repurchasers. But it does mean book-value and ROE metrics are meaningless here, and the leverage is real: interest expense $2.25B/yr, interest coverage ~5×.
6. Valuation — priced in or room?
HCA is genuinely cheap on every earnings-based metric: 14.0× trailing EPS, 13.6× FY26E, 12.4× FY27E, 8.4× FY30E, EV/EBITDA 8.9×, EV/sales 1.8×, FCF yield ~8.7%. That is well below the S&P 500 and reflects the market pricing in policy risk, not a broken business. The bull case is simply re-rating + buyback: at a still-modest 15× FY27E EPS of $33.18 you get ~$500; at 16.5× on a beat you get ~$578. The bear case is a policy-driven earnings and multiple hit to ~12× on ~$30 → ~$360.
Note the PEG-style tension: trailing PEG screens attractive (~0.5), but the forward growth is only mid-single-digit organic, so the cheapness is partly justified — you are being paid to hold policy risk. Street targets (context): consensus $504.73, high $635, low $413. Our $500 base is right on consensus; our bear ($360) is below the Street's low ($413) because we take the subsidy-expiry scenario seriously. Not a deep-value trap, but not a mispriced steal either — a fair-to-cheap operator with a live catalyst risk.
7. Technicals (from the tech block)
Trend: down. $410 sits below the 50-DMA ($404) and well below the 200-DMA ($460); the stock is in a corrective downtrend. MACD −1.1 (negative).
Location:−24.7% off the 52-week high ($545), +22.8% off the 52-week low ($334). The −24.7% drawdown is the max drawdown from peak — a meaningful de-rating already happened.
Momentum: RSI(14) 69.5 — near-overbought after a bounce off the lows, so short-term the easy rebound may be spent.
Relative strength (the tell): HCA +5.4% 12-mo vs SPY +20.6% and QQQ +30.3%; −13.5% 3-mo vs SPY +13.7%. Persistent, heavy underperformance — the market has been de-rating this name, consistent with the policy overhang.
Read: technicals do not confirm a clean uptrend — this is a value setup in a downtrend, with RSI stretched near-term. A patient entry (a pullback toward the low-$390s / rising 50-DMA, or a policy-clarity catalyst) is lower-risk than chasing the RSI-69 bounce.
8. Moat & competitive position
HCA's moat is regional scale and density, not a franchise: in its core Sun Belt markets it owns enough hospitals, ERs and surgery centers to be the dominant network, which gives it leverage with commercial payers and referral-flow advantages. Scale also lets it absorb labor and supply-cost inflation better than smaller systems. But it is a price-taker on government reimbursement (Medicare/Medicaid rates are set by policy), and its fortunes swing with payer mix — so the moat protects share and cost, not pricing power on ~half its revenue.
Peer set (market cap, from data): Tenet Healthcare $17.5B (the closest pure-play hospital comp), plus a broader "healthcare" basket FMP tags as peers — CVS $134B, Pfizer $139B, Vertex $134B, Bristol-Myers $119B, Medtronic $106B, GSK $107B, Sanofi $104B, McKesson $92B, Stryker $125B. Most of those are pharma/med-device/distribution and are not true operating comps; Tenet (THC) and (not in this list) Community Health / Universal Health are the real acute-care peers. Against Tenet, HCA is far larger, more diversified and higher-quality, and trades at a comparable-to-modest multiple.
9. Management, capital allocation & guidance
Capital allocation (the core skill): disciplined, shareholder-friendly, and aggressive. HCA returned $10.07B via buybacks + $0.68B dividends in FY25 — essentially all of FCF plus incremental debt — shrinking the share count from ~339M (2020) to ~227M (Q1'26), a ~33% reduction. This is the primary EPS driver and it is well-executed at a ~9% FCF yield (buying back stock this cheap is accretive). The flip side: it is debt-funded (3.1× leverage) and leaves negative book equity.
Dividend: quarterly $0.78/share (raised; ~0.7% yield) — secondary to buybacks by design.
Insider activity: recent Form 4s are routine director equity awards and a CFO gift transaction (2026-05) — no cluster of alarming discretionary open-market selling in the sampled window. The Frist family (founders) remain 10%+ owners — aligned, long-term.
Management's own guidance (half-weighted — this is management's self-interested voice): per the SEC 8-K earnings release dated 2026-04-24, management reaffirmed its full-year 2026 guidance originally issued 2026-01-27, citing expectations for volume growth and a "mostly stable operating environment," while explicitly flagging risk from "the expiration of the enhanced premium tax credits" (ACA subsidies) and Medicaid directed/supplemental payment approvals. Caveat: the specific dollar guidance ranges (revenue / adjusted EBITDA / EPS) were presented in a reconciliation table that was not captured in the release text we ingested, so we do not quote precise guidance figures — we can confirm only that guidance was reaffirmed, not raised or cut, and that management itself names the ACA-subsidy expiry as the key swing factor. Treat as management's own book, half-weighted.
10. Catalysts & what to watch
Next earnings: 2026-07-24 (Q2'26; Street EPS $7.37, revenue ~$19.4B). Watch same-facility admissions/volume growth and payer mix commentary — the two variables that move the stock.
ACA enhanced premium tax credits: whether they are extended, allowed to expire, or phased — the single biggest swing factor. Expiry would raise the uninsured count and pressure exchange-driven volumes/mix. This is the crux of both the bear case and the current de-rating.
Medicaid supplemental/directed payment programs: state-level approvals (and any federal changes) directly hit revenue — Q1'26 benefited from some of these; their durability matters.
Buyback pace: ~$9.2B remained under authorization as of Q1'26 — continued repurchase at these prices is EPS-accretive; a pause would be a tell.
Labor cost trend: contract-labor normalization has been a tailwind; re-acceleration would compress margins.
Thesis tripwires (what would change the call): ACA subsidies expire with a material volume/mix hit; two consecutive quarters of same-facility volume decline; net-debt/EBITDA drifting above ~3.5×; or the buyback pausing (removes the main EPS lever).
11. Key risks
US health-policy shock (structural, and the reason it's cheap): expiry of ACA enhanced premium tax credits → more uninsured/underinsured and worse payer mix; Medicaid directed/supplemental payment changes. Management itself names this in its guidance caveats (§9).
Leverage: 3.1× net-debt/EBITDA and negative book equity leave less cushion than the cheap P/E implies; a downturn in EBITDA magnifies equity risk.
Reimbursement price-taking: ~half of revenue is government-paid at policy-set rates — limited pricing power on that slice.
Labor/cost inflation: wages and contract labor are the largest cost lever; a re-acceleration compresses the 20% EBITDA margin.
No expert corroboration: unlike a conviction-track name, there is zero independent expert coverage in the Synthos KB — the entire call rests on the numbers, so treat conviction as Low.
Cyclicality/volume: admissions can soften (as in Q1'26's weak respiratory season), and elective-procedure volumes are economically sensitive.
12. Verdict, position sizing & monitoring
Buy — Tactical. HCA is a cheap (13.6× FY26E, 8.9× EV/EBITDA), high-return (~19% ROIC), ~9%-FCF-yield operator that returns essentially all its cash to shareholders and shrinks its share count relentlessly — and our independent base-case fair value (~$500, +22%) lands right on the Street's $504.73. But three things keep it out of the Core sleeve: (1) no expert breadth — zero KB coverage, so conviction is Low; (2) real leverage and negative book equity; and (3) a live policy catalyst (ACA subsidy expiry / Medicaid changes) that is actively de-rating the stock and sits in a technical downtrend. That combination — cheap value + identifiable catalyst risk — is the definition of a tactical buy, not a core compounder.
Sizing:tactical/value satellite, ~2–3% — sized for a re-rating trade with policy risk, not a long-term core hold. Given the RSI-69 bounce and downtrend, scaling in on weakness (toward the low-$390s or after policy clarity) beats chasing.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print and on any ACA-subsidy legislative development. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $410.50.
Single biggest risk: US health-policy — expiry of ACA enhanced premium tax credits and Medicaid payment changes hitting payer mix. That risk is the discount; the tactical bet is that it is more than priced in.
Provenance & disclosures
Traceability:0 KB claims, breadth 0 — HCA has no expert coverage in the Synthos knowledge base. No claim_ids are cited because none exist; the verdict is explicitly fundamentals- and quant-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation), and we do not manufacture it here.
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: 2026 guidance was reaffirmed per the SEC 8-K dated 2026-04-24; specific dollar ranges were in a reconciliation table not captured in the ingested text, so none are quoted — management's own words, half-weighted.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").